Optimization of composition and technology for tablets containing aspen bark extract
DOI:
https://doi.org/10.14739/2409-2932.2015.1.41379Keywords:
Tablets, Plant Extracts, Research DesignAbstract
Summary. Influence of quantitativefactorsof basic quality parameters has been investigated for tabletscontainingextractofaspenbark, receivedbydirect pressingmethodand mathematicalplanningof experiment.To set the optimal composition of tablets containingaspen bark extract the proportion ofProsolv 90, Ludiflash and Polyplasdone XL 10 has been studied. The relationship between the studied factors and parameters of tablets’ regression models has been described. As a result tablets containing aspen bark extractwith mentioned above formula match necessary pharmaco-technological parameters of State Pharmacopoeia of Ukraine.
Introduction.Peptic and duodenal ulcer are serious problems in modern medicine. According to statistics this disease is found in 12,83 % of the adult population in Ukraine [1]. Among the remedies for treatment and prevention of peptic ulcers we can find herbal medicines that may be used in the treatment of pre-peptic conditions and during an acute period as a means of adjuvant therapy in combination with strong remedies [2]. An antacid, cytoprotective, anti-inflammatory and reparative actions of aspen bark extract were proved by the researches of domestic and foreign scientists [3, 4].
Previously, we researched the mutual influence of excipients on the main indicators of quality of aspen bark extract tablets obtained by direct compression method. Due to these researches the best excipientshave been selected. It is necessary to establish the optimal quantitative proportion of excipients in order to obtain the tablets with suitable parameters that satisfy the requirements of the State Pharmacopoeia of Ukraine (SPU) [5, 6].
Rational selection of excipients requires wide range of studies to obtain the optimal composition of the tablets containing aspen bark extract. Using mathematical planning of the experiment gives the possibility to reduce the number of experiments and to obtain the most detailed results of researches about effects of excipients on the basic parameters of tablet quality.
The aim of investigation.In the previous stages of the experiment, we studied the effect of quantitative factors on pharmaco-technological parameters of tablets. To further study were selected Prosolv 90, Ludiflash and Polyplasdone XL 10.The aim of investigation was to set and study the proportion of excipients selected for developing optimal formula of tablets containing aspen bark extract.
Materials and methods.The tablets based on aspen bark extract, obtained by direct compression method, have beenselected as research object. In the development of technology and tablet form,dry aspen bark extract, obtained by the Department of Pharmacognosyof the National University of Pharmacy,has been used [7]. The dry aspen bark extract is hygroscopic fine powder with particles of anizodiametric shape.Namely, from the group of samples of microcrystalline cellulose (MCC) – Prosolv 90 (Silicified MCC, manufactured by JRS Pharma GMBH & Co KG., Germany), from the group structure-based substances sugars – Ludiflash (combination of mannitolCrospovidone, Povidone and polyvinyl acetate, manufactured by BASF Corp., USA) and from the group of disintegrants – Polyplasdone XL 10 (homopolymer of vinyl pyrrolidone, manufactured by manufactured by Ashland Inc., USA). At establishment of optimal composition of the tablets based on aspen bark extract three excipientsinfluence, and also their correlation in composition of tabletshas been studied [8].
Results and discussion.The optimal formula of selected excipients has been set and their proportions in tablet dosage form at the shorter intervals have beendetermined. The study of each researched factor has been carried out according to 5 levels. As a result of studies we found the optimal number of excipients for tablet formula: Prosolv 90 – 0,054 g, Ludiflash – 0,03 g, Polyplasdone XL 10 – 0,025 g, MCC 102 – 0,0835 g, magnesium stearate – 0,0025 g in one unit of dose medication. As a result tablets of aspen bark extract with mentioned above formula have necessary pharmaco-technological parameters that meet the requirements of SPU: resistance to crushing – 130 H, abrasion – 0,04 % mass uniformity of tablets – ± 2,85%, disintegration – 6 min [9].
Conclusions
- Due to mathematical planning the quantitative impact of significant excipients on pharmaco-technological parameters of tablets based on aspen bark extract: Prosolv 90, LudiflashтаPolyplasdone XLhave been studied.
- Due to the regression analysis optimal composition of tablets based on aspen bark extract : dry aspen bark extract – 0,05 g, Prosolv 90 – 0,054 g, Ludiflash – 0,03 g, Polyplasdone XL 10 – 0,025 g, MCC 102 – 0,0835 g,Neusilin US 2 – 0,0025 g, talc –0,0025 g, magnesium stearate – 0,0025 ghas been determined. As a result tablets of aspen bark extract with mentioned above formula have necessary pharmaco-technological parameters that meet the requirements of SPU.
References
Anishchenko, O. V. (Ed.) (2011) Medyko-demohrafichna sytuaciia ta orhanizaciia medychnoi dopomohy naselenniu u 2010 rotsi: pidsumky diialnosti systemy okhorony zdorovia ta realizatsia Prohramy ekonomichnykh reform na 2010–2014 roky «Zamozhne suspilstvo, konkurentnospromozhna ekonomika, efektyvna derzhava» [Medical and demographic situation and organization of medical care for population in 2010: results of the health system activity and the implementation of the program of economic reforms in 2010–2014 «Prosperous Society, Competitive Economics, Effective State»]. Kyiv. [in Ukrainian].
Pasieshvili, L. M. (2009) Pepticheskaya yazva i khronicheskij gastrit: dostizheniya i perspektivy [Peptic ulcer and chronic gastritis: achievements and prospects]. Suchasna hastroenterolohiia, 4(48), 94–99. [in Ukrainian].
Onуshkiv, О. І., Kovalov, S. V., Borodina, N. V., & Groshovyi, T. A. (2009) Osyka yak perspektyvne dzherelo novykh likarskykh zasobiv [Aspen as perspective source of new drugs]. Farmatsevtychnyi chasopys, 3, 16–22. [in Ukrainian].
Tureckova, V. F., Lobanov I. Yu., Rassypnova, S. S., & Talykova, N. M. (2011) Osina obyknovennaya kak perspektivnyj istochnik polucheniya preparatov protivoyazvennogo i protivovospalitel'nogo dejstviya [Typical aspen as a future source for receiving medications with anti-peptic and anti-inflammatory actions]. Byulleten' sibirskoj mediciny, 5, 106–111. [in Russian].
Onyshkiv, O. I., & Groshovyi, T. A. (2011) Vybir dopomizhnykh rechovyn z metoiu otrymannia tabletok na osnovi fitoekstraktu kory osyky [Selection of excipients to obtain tablets based on aspen bark extract]. Farmatsevtychnyi chasopys, 3, 38–42. [in Ukrainian].
Onyshkiv, O. I. (2012) Vyvchennia vplyvu kilkisnykh faktoriv na farmako-tekhnolohichni pokaznyky yakosti tabletok z fitoekstraktom kory osyky [Research of the influence of quantitative factors on the pharmaco-technological characteristics of tablets based on phytoextracts aspen bark]. Fitoterapiia, 1, 82–85. [in Ukrainian].
Borodina, N. V., Kovalev, S. V., Dykyy, I. L., Derkach, N. V., & Maloshtan, V. A. (2004). Patent N 2003054434 Ukraine, MPK A61K 36/89, A61K 36/89, A61P 13/12, A61P 23/00, A61P 25/04, A61P 29/00, A61P 31/04. The method of selection of biologically active substances from the bark of aspen that exhibit antimicrobial, restorative, anti-inflammatory, analgesic and diuretic activity. An applicant and patent holder. National University of Pharmacy. ap pl. 19.05.2003; publ. 15.12.2004, Bull., 12. [in Ukrainian].
Groshovyi, T. A., Martseniuk, V. P., Kucherenko, L. I., & Ghureieva, S. M. (2008) Matematyche planuvannia eksperymenru pry provedenni naukovykh doslidzhen v farmatsii [Mathematical planning of the experiment during the research experiment in pharmacy]. Ternopil: Ukrmedknyha. [in Ukrainian].
Onyshkiv, O. I, Groshovyi, T. A., Kovalev, S. V., Borodina, N. V., Derkach, N. V., & Maloshtan, L. M. (2012). Patent N 70513 Ukraine, MPK A61K 36/00. The medicinal form on the basis of aspen bark. An applicant and patent holder. I. Ya Horbachevsky Ternopil State Medical University. u201115380; appl. 26.12.11; publ. 11.06.12. Bull., 11. [in Ukrainian].
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
